Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-09-12
2006-09-12
Brumback, Brenda (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C514S012200, C530S350000, C530S399000
Reexamination Certificate
active
07105168
ABSTRACT:
The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.
REFERENCES:
patent: 5919899 (1999-07-01), Persico et al.
patent: 2 332 373 (1999-06-01), None
patent: WO 97/14307 (1997-04-01), None
patent: WO 98/00493 (1998-01-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 99/40197 (1999-08-01), None
Maglione et al., Proc Natl Acad Sci USA 1991, vol. 88(20): pp. 9267-9271.
Michael, K. (2000). Relationship of skeletal muscle atrophy to functional status: A systematic research review. Biological Research Nursing. 2(2):117-131.
Ngo et al. (1994). Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction. Birkhauser:Boston, pp. 492-495.
Wells, J.A. (1990). Additivity of mutational effects in proteins. Biochemistry 29:8529-8517.
Pettit et al. (1998). The developmemt of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Trends Biotechnol 16: 343-349.
Breier, “Expresion of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation”, Development, vol. 114, 1992, pp. 521-532.
Cao, “In vivo Angiogenic Activity and Hypoxia Induction of Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor”, J. Clin. Invest., vol. 98, 1996, pp. 2507-2511.
Carmeliet, “VEGF gene therapy: stimulating angiogenesis or angioma-gensis?”, Nature Medicine, vol. 6, No. 10, Oct. 2000, pp. 1102-1103.
Carmeliet, “Synergism between vascular enodthelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions”, Nature Medicine, vol. 7, No. 5, May 2001, pp. 575-583.
Conn, “Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line”, Prod. Natl Acad.Sa., vol. 87, Feb. 1990, pp. 1323-1327.
Connolly, “Human Vascular Permeability Factor”, The Journal of Biological Chemistry, vol. 264, No. 33, Nov. 25, 1989, pp. 20017-20024.
Connolly, “Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis”, J. Clin. Invest., vol. 84, Nov. 1989, pp. 1470-1478.
Connolly, “Vascular Permeability Factor: A Unique Regulator of Blood Vessel Function”, Journal of Cellular Biochemistry, No. 47, 1991, pp. 219-223.
Couffinhal, “Impaired Collateral Vessel Developmemt Associated With Reduced Expression of Vascular Endothelial Growth Factor in ApoE—Mice”, J. Am. Heart Assn, 1999, pp. 3188-3198.
Deindl, “Role of Ischemia and of Hypoxia-Inducible Genes in Arteriogenesis After Femoral Artery Occlusion in the Rabbit”, J. Am. Heart Assn., 2001, pp. 779-786.
DiSalvo, “Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor—Placenta Growth Factor Heterodimer”, Journal of Biological Chemistry, vol. 270, No. 13, Mar. 31, 1995, pp. 7717-7723.
Ferrara, “The Vascular Endothelial Growth Factor Family of Polypeptides”, Journal of Cellular Biochemistry, vol. 27, 1991, pp. 211-218.
Henzel, “Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells”, Biochem Biophys Res Coomun., vol. 161, No. 2, Jun. 15, 1989, pp. 851-858.
Folkman, “Angiogenesis”, Journal of Biological Chemistry, vol. 267, No. 16, Jun 5, 1992, pp. 10931-10934.
Gospodarowicz, “Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells”, Proc. Natl. Acad. Sci., vol. 86, Oct. 1989, pp. 7311-7315.
Klagsbrun, “Regulators of Angiogenesis”, Annu. Rev. Physiol., vol. 53, 1991, pp. 217-239.
Hariawala, “VEGF Improves Myocardial Blood Flow but Produces EDRF-Mediated Hypotension in Porcine Hearts”, Journal of Surgical Research, vol. 63, pp. 77-82.
Henry, “The VIVA Trial”, Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis, J. Am. Heart Assn., 2003, pp. 1359-1365.
Isner, “Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization”, vol. 103, No. 9, May 1999, pp. 1231-1236.
Levy, “An Endothelial Cell Growth Factor from the Mouse Neuroblastoma Cell Line NB41”, Growth Factors, vol. 2, 1989, pp. 9-19.
Maglione, “Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor”, Proc. Natl. Acad. Sci., vol. 88, Oct. 1991, pp. 9267-9271.
Frelin, “VEGF: A Mediation of Hypoxic Angiogenesis,” Medicine Sciences 13:886-892 (1997).
Carmeliet Peter
Collen Desire
Brumback Brenda
Clark & Elbing LLP
D. Collen Research Foundation vzw
Lockard Jon M
LandOfFree
Method of improving ischemic muscle function by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of improving ischemic muscle function by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of improving ischemic muscle function by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3564876